Header Logo

Connection

CHING-WEI DAVID TZENG to Pancreatic Neoplasms

Back to Details
This is a "connection" page, showing publications CHING-WEI DAVID TZENG has written about Pancreatic Neoplasms.
CHING-WEI DAVID TZENG
Connection Strength
7.901
Pancreatic Neoplasms
  1. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490.
    View in: PubMed
    Score: 0.260
  2. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. J Surg Oncol. 2022 Nov; 126(6):1021-1027.
    View in: PubMed
    Score: 0.251
  3. Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. J Gastrointest Surg. 2022 02; 26(2):352-359.
    View in: PubMed
    Score: 0.244
  4. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Surg Oncol. 2022 Mar; 40:101673.
    View in: PubMed
    Score: 0.241
  5. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. J Surg Oncol. 2021 Dec; 124(8):1381-1389.
    View in: PubMed
    Score: 0.236
  6. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4623-4624.
    View in: PubMed
    Score: 0.228
  7. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Aug; 28(8):4615-4622.
    View in: PubMed
    Score: 0.227
  8. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1570-1571.
    View in: PubMed
    Score: 0.221
  9. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1563-1569.
    View in: PubMed
    Score: 0.221
  10. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX. Pancreas. 2019 07; 48(6):837-843.
    View in: PubMed
    Score: 0.204
  11. Inpatient Opioid Use After Pancreatectomy: Opportunities for Reducing Initial Opioid Exposure in Cancer Surgery Patients. Ann Surg Oncol. 2019 Oct; 26(11):3428-3435.
    View in: PubMed
    Score: 0.204
  12. ASO Author Reflections: Temporary Mesocaval Shunt: Indications and Technique for Safe Resection of Pancreatic Tumors With Mesenteric Venous Occlusion. Ann Surg Oncol. 2019 12; 26(Suppl 3):579-580.
    View in: PubMed
    Score: 0.200
  13. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing. HPB (Oxford). 2019 09; 21(9):1203-1210.
    View in: PubMed
    Score: 0.199
  14. Contemporary analysis of complications associated with biliary stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB (Oxford). 2019 06; 21(6):662-668.
    View in: PubMed
    Score: 0.196
  15. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford). 2019 07; 21(7):841-848.
    View in: PubMed
    Score: 0.196
  16. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. J Surg Oncol. 2018 Jun; 117(8):1648-1654.
    View in: PubMed
    Score: 0.188
  17. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. J Surg Res. 2017 06 15; 214:1-8.
    View in: PubMed
    Score: 0.174
  18. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep; 114(4):451-5.
    View in: PubMed
    Score: 0.165
  19. Increased morbidity and mortality of a concomitant colectomy during a pancreaticoduodenectomy: an NSQIP propensity-score matched analysis. HPB (Oxford). 2015 Sep; 17(9):846-54.
    View in: PubMed
    Score: 0.155
  20. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. J Gastrointest Surg. 2014 Jan; 18(1):16-24; discussion 24-5.
    View in: PubMed
    Score: 0.138
  21. Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification. J Gastrointest Surg. 2014 Jan; 18(1):146-55; discussion 155-6.
    View in: PubMed
    Score: 0.137
  22. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014 May; 16(5):430-8.
    View in: PubMed
    Score: 0.136
  23. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 2013 Jul; 20(7):2197-203.
    View in: PubMed
    Score: 0.131
  24. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012 Jun; 14(6):365-72.
    View in: PubMed
    Score: 0.123
  25. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 2012 Jun; 19(6):2045-53.
    View in: PubMed
    Score: 0.122
  26. EGFR genomic gain and aberrant pathway signaling in pancreatic cancer patients. J Surg Res. 2007 Nov; 143(1):20-6.
    View in: PubMed
    Score: 0.091
  27. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann Surg Oncol. 2007 Jul; 14(7):2150-8.
    View in: PubMed
    Score: 0.088
  28. Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery. 2007 Apr; 141(4):464-9.
    View in: PubMed
    Score: 0.086
  29. Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024 Mar 02; 111(3).
    View in: PubMed
    Score: 0.070
  30. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
    View in: PubMed
    Score: 0.070
  31. ASO Author Reflections: The Value of Serum CEA for Prognostication at Staging and Response Evaluation in Patients with Localized Pancreatic Adenocarcinoma and Nonelevated CA19-9. Ann Surg Oncol. 2024 03; 31(3):1842-1843.
    View in: PubMed
    Score: 0.070
  32. Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
    View in: PubMed
    Score: 0.070
  33. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 Dec; 24(12):1387-1398.
    View in: PubMed
    Score: 0.069
  34. Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma. Surg Oncol. 2023 Dec; 51:101994.
    View in: PubMed
    Score: 0.068
  35. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma. Ann Surg Oncol. 2023 Oct; 30(11):6662-6670.
    View in: PubMed
    Score: 0.067
  36. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. Ann Surg. 2023 07 01; 278(1):22-30.
    View in: PubMed
    Score: 0.066
  37. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Am J Surg Pathol. 2023 04 01; 47(4):421-430.
    View in: PubMed
    Score: 0.065
  38. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest. 2022 12 15; 132(24).
    View in: PubMed
    Score: 0.065
  39. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. J Gastrointest Surg. 2023 02; 27(2):319-327.
    View in: PubMed
    Score: 0.065
  40. Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. Cancer Discov. 2022 10 05; 12(10):2330-2349.
    View in: PubMed
    Score: 0.064
  41. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. J Hepatobiliary Pancreat Sci. 2023 Jan; 30(1):e1-e2.
    View in: PubMed
    Score: 0.063
  42. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3.
    View in: PubMed
    Score: 0.063
  43. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.063
  44. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. J Natl Compr Canc Netw. 2022 07; 20(7):783-791.e1.
    View in: PubMed
    Score: 0.063
  45. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022 05 09; 114(5):695-703.
    View in: PubMed
    Score: 0.062
  46. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database. Ann Surg Oncol. 2022 Jan; 29(1):342-351.
    View in: PubMed
    Score: 0.059
  47. GRP78 expression and prognostic significance in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant therapy versus surgery first. Pancreatology. 2021 Oct; 21(7):1378-1385.
    View in: PubMed
    Score: 0.059
  48. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.059
  49. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. J Surg Oncol. 2021 May; 123(6):1414-1422.
    View in: PubMed
    Score: 0.058
  50. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.058
  51. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology. 2021 Aug; 21(5):942-949.
    View in: PubMed
    Score: 0.058
  52. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021 Jan; 21(1):200-207.
    View in: PubMed
    Score: 0.056
  53. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.055
  54. External Retraction Technique for Robotic Pancreatoduodenectomy. J Am Coll Surg. 2020 11; 231(5):e8-e10.
    View in: PubMed
    Score: 0.055
  55. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.054
  56. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Ann Surg Oncol. 2020 Oct; 27(10):3939-3947.
    View in: PubMed
    Score: 0.054
  57. Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study. J Phys Act Health. 2019 12 01; 16(12):1113-1122.
    View in: PubMed
    Score: 0.052
  58. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019 08 08; 178(4):795-806.e12.
    View in: PubMed
    Score: 0.051
  59. Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. J Gastrointest Surg. 2020 02; 24(2):368-379.
    View in: PubMed
    Score: 0.050
  60. Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Adjusted Analysis. Pancreas. 2019 02; 48(2):216-222.
    View in: PubMed
    Score: 0.050
  61. Pancreaticoduodenectomy with Mesocaval Shunt for Locally Advanced Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):652.
    View in: PubMed
    Score: 0.049
  62. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clin Cancer Res. 2019 Apr 01; 25(7):2194-2205.
    View in: PubMed
    Score: 0.049
  63. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.049
  64. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg. 2019 07; 218(1):145-150.
    View in: PubMed
    Score: 0.048
  65. Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard? Ann Surg. 2018 08; 268(2):223-224.
    View in: PubMed
    Score: 0.048
  66. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. Anticancer Res. 2018 Jul; 38(7):4035-4039.
    View in: PubMed
    Score: 0.048
  67. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol. 2018 Jun; 25(6):1709-1715.
    View in: PubMed
    Score: 0.047
  68. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg. 2018 03; 267(3):552-560.
    View in: PubMed
    Score: 0.046
  69. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.046
  70. Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. J Gastrointest Surg. 2018 04; 22(4):703-712.
    View in: PubMed
    Score: 0.046
  71. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.045
  72. Tips and tricks of splenic vessel preservation during laparoscopic distal pancreatectomy. Surg Endosc. 2018 04; 32(4):2149-2150.
    View in: PubMed
    Score: 0.045
  73. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology. 2015 Nov-Dec; 15(6):667-73.
    View in: PubMed
    Score: 0.039
  74. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.039
  75. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Acta Oncol. 2016; 55(3):265-77.
    View in: PubMed
    Score: 0.039
  76. Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). HPB (Oxford). 2014 Apr; 16(4):350-6.
    View in: PubMed
    Score: 0.034
  77. Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system. Ann Surg Oncol. 2013 Dec; 20(13):4073-9.
    View in: PubMed
    Score: 0.034
  78. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol. 2013 Sep; 14(3):293-310.
    View in: PubMed
    Score: 0.034
  79. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:S500-8.
    View in: PubMed
    Score: 0.033
  80. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther. 2010 Sep 15; 10(6):555-63.
    View in: PubMed
    Score: 0.028
  81. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am J Surg. 2010 Sep; 200(3):398-405.
    View in: PubMed
    Score: 0.027
  82. Surgical Eligibility Does Not Imply Surgical Equity: Recommendations for Curative Treatment in Patients With Stage I/II Pancreatic Head Adenocarcinoma Differ by Age and Race. Ann Surg. 2023 02 01; 277(2):321-328.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.